Company Description
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases.
Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation.
It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.
| Country | United States |
| Founded | 2017 |
| IPO Date | Feb 13, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 22 |
| CEO | Tien-Li Lee |
Contact Details
Address: 4370 La Jolla Village Drive, Suite 1050 San Diego, California 92122 United States | |
| Phone | 858 225 7696 |
| Website | aardvarktherapeutics.com |
Stock Details
| Ticker Symbol | AARD |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001774857 |
| Employer ID | 82-1606367 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Tien-Li Lee M.D. | Chief Executive Officer, Secretary and Director |
| Dr. Bryan Jones Ph.D. | Chief Operating Officer |
| Dr. Manasi Sinha Jaiman M.D., M.P.H. | Chief Medical Officer |
| Nelson B. Sun M.B.A. | Chief Financial Officer |
| Dr. Andreas Niethammer M.D., Ph.D. | Head of Translational Medicine |
| Dr. Dvorit Samid Ph.D. | Executive Vice President of Medical Affairs |
| Dr. Zhenhuan Zheng Ph.D. | Chief Research Officer |
| Tom Bicsak Ph.D. | Head of Regulatory Affairs and Quality |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 31, 2025 | 10-K | Annual Report |
| Mar 31, 2025 | 8-K | Current Report |
| Feb 24, 2025 | SCHEDULE 13G | Filing |
| Feb 24, 2025 | SCHEDULE 13G | Filing |
| Feb 24, 2025 | SCHEDULE 13G | Filing |
| Feb 14, 2025 | 8-K | Current Report |
| Feb 13, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 13, 2025 | 424B4 | Prospectus |
| Feb 12, 2025 | EFFECT | Notice of Effectiveness |
| Feb 12, 2025 | CERT | Certification by an exchange approving securities for listing |